You don’t say.

Transgender women face prostate cancer risk, says first-of-its-kind study from UCSF

Of course they do: because they are men.

Transgender women have a small but meaningful risk of prostate cancer, but traditional screening tools may not work well for them, especially if they’re taking estrogen for gender-affirming care, according to a national study led by UCSF researchers.

Or rather, especially if they’re mucking up their bodies by taking estrogen to foster a delusion that they’re women. “Gender-affirming care” is a misnomer, and medical researchers shouldn’t be using it. “Gender affirmation” isn’t medical.

The research, published Saturday in the journal JAMA, is the first in the U.S. to look at prostate cancer in transgender women. It underscores the need to improve overall health care for transgender people, who are underrepresented in medical research and who experience worse outcomes than cisgender patients for all kinds of health issues.

Perhaps because they’re recklessly tampering with their bodies?

Transgender people, who are thought to make up less than 1% of the population, have mostly been left out of large studies of all kinds of health issues. When the UCSF team decided to look at prostate cancer in transgender women, the first problem they ran into was finding patients. Generally, “transgender” isn’t noted in patients’ medical records, so scientists had to look for secondary clues like estrogen prescriptions or a diagnosis of gender dysphoria.

Not noted in patients’ medical records! Gee, you think that might be a bad idea?

10 Responses to “Risky”